In the BioHarmony Drug Report Database
Giapreza (angiotensin ii) is a protein pharmaceutical. Angiotensin ii was first approved as Giapreza on 2017-12-21. It is used to treat hypotension in the USA. It has been approved in Europe to treat hypotension and shock. It is known to target type-2 angiotensin II receptor, proto-oncogene Mas, potassium channel subfamily K member 3, and type-1 angiotensin II receptor. Giapreza’s patents are valid until 2034-12-18 (FDA).
Image (chem structure or protein)